In phase III TYTAN trial, the addition of lapatinib to weekly paclitaxel in second-line setting improved overall response rate in patients with HER-2-positive gastric adenocarcinomas (odds ratio, 3.85; 95% CI, 1.80–8.87, P < 0.001) but did not significantly improve overall survival (lapatinib+paclitaxel, 11.0 versus paclitaxel, 8.9 months; P = 0.104) [26]. Here, ERBB2 is linked to gastric adenocarcinoma.